|
6 Companies |
|
7 Products |
|
7 Products |
|
9 Mechanisms of Action |
|
0 Trials |
|
50 News |
|
- | NN1213 / Novo Nordisk
Enrollment change: Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome (clinicaltrials.gov) - Apr 26, 2019
P=N/A, N=31, Completed, Sponsor: University of Kansas Medical Center
N=52 --> 31
- | Trial completion, Trial primary completion date: Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome (clinicaltrials.gov) - Dec 28, 2017
P=N/A, N=52, Completed, Sponsor: University of Kansas Medical Center
N=52 --> 31 Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Oct 2016
- | beloranib (ZGN-440) / Larimar Therap
Trial termination: bestPWS: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Dec 15, 2016
P3, N=108, Terminated, Sponsor: Zafgen, Inc.
Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Oct 2016 Active, not recruiting --> Terminated; FDA Clinical Hold
- Trial completion, Enrollment change, Trial primary completion date: Prader-Willi Syndrome Macronutrient Study (clinicaltrials.gov) - Dec 14, 2016
P=N/A, N=10, Completed, Sponsor: Duke University
Active, not recruiting --> Terminated; FDA Clinical Hold Recruiting --> Completed | N=13 --> 10 | Trial primary completion date: Sep 2016 --> May 2016
- Byetta (exenatide) / AstraZeneca
Trial completion, Enrollment change: Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome (clinicaltrials.gov) - Sep 29, 2016
P=N/A, N=10, Completed, Sponsor: Children's Hospital Los Angeles
Recruiting --> Completed | N=13 --> 10 | Trial primary completion date: Sep 2016 --> May 2016 Active, not recruiting --> Completed | N=20 --> 10
- | diazoxide choline controlled release (DCCR) / Soleno Therap
Trial completion, Phase classification: Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome (clinicaltrials.gov) - Sep 1, 2016
P1/2, N=13, Completed, Sponsor: Essentialis, Inc.
Active, not recruiting --> Completed | N=20 --> 10 Active, not recruiting --> Completed | Phase classification: P1 --> P1/2
- beloranib (ZGN-440) / Larimar Therap
Phase classification: An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Jul 18, 2016
P2a, N=17, Completed, Sponsor: Zafgen, Inc.
Active, not recruiting --> Completed | Phase classification: P1 --> P1/2 Phase classification: P2 --> P2a
- Enrollment open, Enrollment change, Trial primary completion date: Prader-Willi Syndrome Macronutrient Study (clinicaltrials.gov) - Mar 14, 2016
P=N/A, N=13, Recruiting, Sponsor: Duke University
Phase classification: P2 --> P2a Active, not recruiting --> Recruiting | N=10 --> 13 | Trial primary completion date: Apr 2016 --> Sep 2016
- Enrollment closed, Trial primary completion date: Prader-Willi Syndrome Macronutrient Study (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=10, Active, not recruiting, Sponsor: Duke University
Active, not recruiting --> Recruiting | N=10 --> 13 | Trial primary completion date: Apr 2016 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Apr 2016
- Victoza (liraglutide) / Novo Nordisk
Trial termination: Liraglutide Use in Prader-Willi Syndrome (clinicaltrials.gov) - Dec 10, 2015
P4, N=1, Terminated, Sponsor: Vancouver General Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Apr 2016 Active, not recruiting --> Terminated; Subject withdrew
- oxytocin / Generic mfg.
Trial completion: Oxytocin Trial in Prader-Willi Syndrome (clinicaltrials.gov) - Sep 18, 2015
P1, N=24, Completed, Sponsor: University of Florida
Active, not recruiting --> Terminated; Subject withdrew Recruiting --> Completed
- Enrollment open, Enrollment change, Trial primary completion date: Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome (clinicaltrials.gov) - Jun 29, 2015
P=N/A, N=60, Recruiting, Sponsor: Merlin G. Butler, MD, PhD
Recruiting --> Completed Active, not recruiting --> Recruiting | N=36 --> 60 | Trial primary completion date: Apr 2014 --> Jul 2017
- ||||| beloranib (ZGN-440) / Larimar Therap
Enrollment closed: bestPWS: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Jun 3, 2015
P3, N=102, Active, not recruiting, Sponsor: Zafgen, Inc.
Active, not recruiting --> Recruiting | N=36 --> 60 | Trial primary completion date: Apr 2014 --> Jul 2017 Recruiting --> Active, not recruiting
- oxytocin / Generic mfg.
Enrollment open, Trial initiation date: Oxytocin Trial in Prader-Willi Syndrome (clinicaltrials.gov) - May 26, 2015
P1, N=24, Recruiting, Sponsor: University of Florida
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Mar 2015
- Norditropin (somatropin) / Novo Nordisk
Trial completion, Enrollment change: Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome (clinicaltrials.gov) - Apr 7, 2015
P=N/A, N=46, Completed, Sponsor: Karolinska University Hospital
Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Mar 2015 Active, not recruiting --> Completed | N=75 --> 46
- ||||| beloranib (ZGN-440) / Larimar Therap
Enrollment change: bestPWS: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Jan 30, 2015
P3, N=102, Recruiting, Sponsor: Zafgen, Inc.
Active, not recruiting --> Completed | N=75 --> 46 N=84 --> 102
- diazoxide choline controlled release (DCCR) / Soleno Therap
Enrollment closed: Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome (clinicaltrials.gov) - Jan 28, 2015
P1, N=12, Active, not recruiting, Sponsor: Essentialis, Inc.
N=84 --> 102 Recruiting --> Active, not recruiting
- Norditropin (somatropin) / Novo Nordisk
Trial initiation date: Retrospective Observational Study on Efficacy and Safety of Norditropin (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=41, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Initiation date: Mar 2008 --> Nov 2008
- diazoxide choline controlled release (DCCR) / Soleno Therap
Trial primary completion date: Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome (clinicaltrials.gov) - Nov 14, 2014
P1, N=12, Recruiting, Sponsor: Essentialis, Inc.
Initiation date: Mar 2008 --> Nov 2008 Trial primary completion date: Oct 2014 --> Feb 2015
- oxytocin / Generic mfg.
Trial initiation date, Trial primary completion date: Oxytocin Trial in Prader-Willi Syndrome (clinicaltrials.gov) - Oct 22, 2014
P1, N=24, Not yet recruiting, Sponsor: University of Florida
Trial primary completion date: Oct 2014 --> Feb 2015 Initiation date: Jun 2014 --> Nov 2014 | Trial primary completion date: Dec 2014 --> Aug 2015
- |||||| beloranib (ZGN-440) / Larimar Therap
Enrollment open, Trial primary completion date: bestPWS: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Oct 2, 2014
P3, N=84, Recruiting, Sponsor: Zafgen, Inc.
Initiation date: Jun 2014 --> Nov 2014 | Trial primary completion date: Dec 2014 --> Aug 2015 Not yet recruiting --> Recruiting | Trial primary completion date: May 2015 --> Oct 2015
- Trial completion, Enrollment change: Hypoglycemia in Prader-Willi Syndrome (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=2, Completed, Sponsor: University of Florida
Not yet recruiting --> Recruiting | Trial primary completion date: May 2015 --> Oct 2015 Recruiting --> Completed | N=20 --> 2
- Clinical protocol, Trial completion, Trial primary completion date: Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=392, Completed, Sponsor: University of Florida
Recruiting --> Completed | N=20 --> 2 Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jan 2014
- | Trial completion: Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome (clinicaltrials.gov) - Aug 21, 2014
P2, N=38, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jan 2014 Recruiting --> Completed
- octreotide acetate solution for injection / Generic mfg.
Enrollment change, Trial termination: Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS) (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=5, Terminated, Sponsor: Duke University
Recruiting --> Completed N=26 --> 5 | Active, not recruiting --> Terminated; Inadequate recruitment
- |||||||||| beloranib (ZGN-440) / Larimar Therap
New P3 trial: bestPWS: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Jul 1, 2014
P3, N=84, Not yet recruiting, Sponsor: Zafgen, Inc.
- Trial primary completion date: Prader-Willi Syndrome Macronutrient Study (clinicaltrials.gov) - May 13, 2014
P=N/A, N=10, Recruiting, Sponsor: Duke University
N=26 --> 5 | Active, not recruiting --> Terminated; Inadequate recruitment Trial primary completion date: Jan 2015 --> Jun 2015
- Trial initiation date: Prader-Willi Syndrome Macronutrient Study (clinicaltrials.gov) - May 13, 2014
P=N/A, N=10, Recruiting, Sponsor: Duke University
Trial primary completion date: Jan 2015 --> Jun 2015 Initiation date: Jan 2014 --> May 2014
- Enrollment open: Prader-Willi Syndrome Macronutrient Study (clinicaltrials.gov) - May 13, 2014
P=N/A, N=10, Recruiting, Sponsor: Duke University
Initiation date: Jan 2014 --> May 2014 Not yet recruiting --> Recruiting
- diazoxide choline controlled release (DCCR) / Soleno Therap
Enrollment open: Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome (clinicaltrials.gov) - Apr 20, 2014
P1, N=12, Recruiting, Sponsor: Essentialis, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- oxytocin / Generic mfg.
Trial initiation date: Oxytocin Trial in Prader-Willi Syndrome (clinicaltrials.gov) - Apr 2, 2014
P1, N=24, Not yet recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting Initiation date: Feb 2014 --> Jun 2014
- | Enrollment open: Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome (clinicaltrials.gov) - Jan 26, 2014
P2, N=38, Recruiting, Sponsor: Ferring Pharmaceuticals
Initiation date: Feb 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- Enrollment closed: Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome (clinicaltrials.gov) - Jan 13, 2014
P=N/A, N=36, Active, not recruiting, Sponsor: Merlin G. Butler, MD, PhD
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | diazoxide choline controlled release (DCCR) / Soleno Therap
New P1 trial: Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome (clinicaltrials.gov) - Jan 9, 2014
P1, N=12, Recruiting, Sponsor: Essentialis, Inc.
- | beloranib (ZGN-440) / Larimar Therap
Trial completion: An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Dec 16, 2013
P2, N=17, Completed, Sponsor: Zafgen, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- oxytocin / Generic mfg.
New P1 trial: Oxytocin Trial in Prader-Willi Syndrome (clinicaltrials.gov) - Dec 15, 2013
P1, N=24, Not yet recruiting, Sponsor: University of Florida
- | New P2 trial: Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome (clinicaltrials.gov) - Oct 21, 2013
P2, N=38, Recruiting, Sponsor: Ferring Pharmaceuticals
- Byetta (exenatide) / AstraZeneca
Enrollment closed: Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome (clinicaltrials.gov) - Jul 24, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: Children's Hospital Los Angeles
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment open: Hypoglycemia in Prader-Willi Syndrome (clinicaltrials.gov) - Jul 14, 2013
P=N/A, N=20, Recruiting, Sponsor: University of Florida
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial completion: Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies (clinicaltrials.gov) - Jun 19, 2013
P1/2, N=5, Completed, Sponsor: University Hospital, Toulouse
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- topiramate / Generic mfg.
Trial completion: Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome (clinicaltrials.gov) - Apr 29, 2013
P=N/A, N=10, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed Recruiting --> Completed
- | beloranib (ZGN-440) / Larimar Therap
New P2 trial: An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Mar 25, 2013
P2, N=17, Completed, Sponsor: Zafgen, Inc.
- Clinical: Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=46, Completed, Sponsor: Samsung Medical Center
- Clinical protocol, Enrollment change: Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=400, Recruiting, Sponsor: University of Florida
Recruiting --> Completed N=300 --> 400
- New P1/2 trial: Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies (clinicaltrials.gov) - Mar 6, 2012
P1/2, N=5, Completed, Sponsor: University Hospital, Toulouse
- Byetta (exenatide) / AstraZeneca
Trial initiation date: Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome (clinicaltrials.gov) - Feb 29, 2012
P=N/A, N=20, Active, not recruiting, Sponsor: Children's Hospital Los Angeles
N=300 --> 400 Initiation date: Nov 2011 --> Mar 2012
- Victoza (liraglutide) / Novo Nordisk
New P4 trial: Liraglutide Use in Prader-Willi Syndrome (clinicaltrials.gov) - Feb 20, 2012
P4, N=1, Active, not recruiting, Sponsor: Vancouver General Hospital
- | Norditropin (somatropin) / Novo Nordisk
Trial completion: Bioequivalence of Two Somatropin Products (Norditropin (clinicaltrials.gov) - Oct 2, 2011
P1, N=30, Completed, Sponsor: Novo Nordisk
Initiation date: Nov 2011 --> Mar 2012 Active, not recruiting --> Completed